Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028966 | 0.95 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL13946946 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL224123 | 0.83 | TDP1 (0.60) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL1531330 | 0.82 | KMT2A (0.54) | SMN1; SMN2ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL31666526 | 0.82 | ALDH1A1 (0.46) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL1929569 | 0.80 | MAPT (0.58) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL2086989 | 0.80 | MAPT (0.61) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL4038925 | 0.80 | MAPT (0.65) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL4199965 | 0.80 | HTT (0.59) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL1144020 | 0.80 | VCP (0.59) | SMN1; SMN2LMNAMAPTHTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012038307-A1 | SPIRO SUBSTITUTED PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES USEFUL AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071499-A1 | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones | CHU XIN-JIE (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071499-A1 | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones | IDO1, IDH3A, H1-3 | SMN1; SMN2 2383/4885LMNA 3373/4885ALDH1A1 261/4885 |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | SMN1; SMN2 2244/4885LMNA 2616/4885ALDH1A1 1370/4885 |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | SMN1; SMN2 2283/4885LMNA 1998/4885ALDH1A1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.